- Luminex begins rollout of next generation of xMAP® Technology, the gold standard for multiplexing of biological tests   - New xMAP® INTELLIFLEX System enables its Life Science Research Partners and customers to explore new applications, including offering a unique ability to simultaneously detect

- Assay uses multiplexing for highly specific and sensitive detection of IgG antibodies against SARS-CoV-2   - Assay runs on all xMAP® platforms, the gold standard for multiplex serological testing, and detects previous infection and potential immunity to SARS-CoV-2   - Company plans to launch

AUSTIN, Texas , May 22, 2020 /PRNewswire/ --   Luminex Corporation (Nasdaq: LMNX) (the "Company"), today announced that its board of directors declared a cash dividend for the second quarter of 2020 of $0.09 per share of common stock payable on July 9, 2020 to stockholders of record as of the close

AUSTIN, Texas , May 8, 2020 /PRNewswire/ --  Luminex Corporation (NASDAQ: LMNX) (" Luminex ") announced today the pricing of its offering of $260,000,000 aggregate principal amount of 3.00% Convertible Senior Notes due 2025 (the "Convertible Notes") in a private placement pursuant to Section

Delivers Accelerated Organic Growth and Return to Profitability AUSTIN, Texas , May 4, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced results for its first quarter ended March 31, 2020 . All amounts in this release are in conformity with U.S.

AUSTIN, Texas , April 22, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the first quarter ended March 31, 2020 on Monday, May 4, 2020 . A press release announcing the results is scheduled for release after the close of trading on that

First Quarter Earnings Call Scheduled for May 11, 2020 AUSTIN, Texas , April 6, 2020 /PRNewswire/ -- Luminex Corporation today announced 1 st quarter 2020 revenues of just over $90 million , up approximately 10% over the 1 st quarter of 2019 and approximately 8% above the top end of its previously

Luminex is now able to provide SARS-CoV-2 diagnostic tests for both high-complexity, high-throughput reference labs and moderate complexity, sample-to-answer testing facilities AUSTIN, Texas , April 6, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the Food and Drug

- Follows BARDA Contract and EUA for NxTAG® CoV Extended Panel last week - ARIES® SARS-CoV-2 Assay will be submitted for EUA later this week AUSTIN, Texas , March 31, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received $642,450 in funding from the Biomedical

BARDA award for $642K helped Luminex accelerate development and validation AUSTIN, Texas , March 27, 2020 /PRNewswire/ --  Luminex Corporation (NASDAQ: LMNX) today announced that the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its NxTAG ®  CoV Extended